Barriers to Diagnosis Access for Chagas Disease in Colombia

Table 1

Main characteristics and study design of the articles included in this review.

Authors (Ref)	Year of publication	Country	Study design	Key findings	CAPS
Manne-Goehler et al. [21]	2015	United States of America	Mixed methods	(1) An inability to place orders for Chagas disease diagnostic tests in institutional laboratory ordering systems, (2) heterogeneity in available diagnostic tests, (3) a limited capacity to conduct definitive confirmatory diagnostic testing, (4) poor follow-up of positive blood donors, (5) diagnostic and institutionalized referral and care processes, (6) lack of financing for patient-care activities, and (7) limited awareness and training among providers	Mixed methods
Manne-Goehler et al. [22]	2014	Mexico	Mixed methods	(1) Lack of market authorization for benznidazole, (2) long waiting times for medicine importation, and (3) limited awareness of the disease among both physicians and patients	Mixed methods
Manne et al. [23]	2013	Mexico	Mixed methods	(1) Exclusion of antitrypanosomal medicines from the national formulary, (2) historical exclusion of Chagas disease from the social insurance package, (3) absence of national clinical guidelines, (4) limited provider awareness, (5) no national clinical guidelines for Chagas disease treatment, (6) global supply chain problems: long waiting times, and (7) insufficient training and education of providers about Chagas disease and its diagnosis and treatment	Mixed methods

Ref: reference; CAPS: Critical Appraisal Skills Programme checklist.